Myriad Genetics
MYGN
233 hedge funds and large institutions have $1.61B invested in Myriad Genetics in 2017 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 96 increasing their positions, 57 reducing their positions, and 29 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
68% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 57
59% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 29
19% more capital invested
Capital invested by funds: $1.35B → $1.61B (+$259M)
5.1% more ownership
Funds ownership: 117.94% → 123.04% (+5.1%)
4% more funds holding
Funds holding: 223 → 233 (+10)
59% less call options, than puts
Call options by funds: $3.62M | Put options by funds: $8.89M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$169M |
| 2 |
D.E. Shaw & Co
New York
|
+$25.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$17.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.9M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$38.1M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$20.7M |
| 3 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$19.2M |
| 4 |
AIM
Assured Investment Management
New York
|
-$16.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.9M |
MYGN Hedge Fund Activity: Q1 2017 in Review
233 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2017, worth a combined $1.61B — up 19% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MYGN positions and 29 closed out — a net gain of 17 holders — while 96 added to existing stakes and 57 trimmed.
The largest buyer was BlackRock, adding an estimated $169M. The largest seller was Renaissance Technologies, cutting an estimated $38.1M.
- 233 institutional investors held Myriad Genetics (MYGN) as of Q1 2017, up from 223 in Q4 2016.
- Funds reported $1.61B of Myriad Genetics stock for Q1 2017, up 19% quarter-over-quarter.
- 46 funds opened new Myriad Genetics positions in Q1 2017 and 29 closed out, a net change of +17 holders.
- The largest Myriad Genetics buyer in Q1 2017 was BlackRock, an estimated $169M added.
- The largest Myriad Genetics seller in Q1 2017 was Renaissance Technologies, an estimated $38.1M sold.
Based on aggregated 13F filings for Q1 2017.